Cargando…

PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage

[Image: see text] Ubiquitin phosphorylation by the mitochondrial protein kinase PTEN-induced kinase 1 (PINK1), upon mitochondrial depolarization, is an important intermediate step in the recycling of damaged mitochondria via mitophagy. As mutations in PINK1 can cause early-onset Parkinson’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambourne, Olivia A., Bell, Shane, Wilhelm, Léa P., Yarbrough, Erika B., Holly, Gabriel G., Russell, Oliver M., Alghamdi, Arwa M., Fdel, Azeza M., Varricchio, Carmine, Lane, Emma L., Ganley, Ian G., Jones, Arwyn T., Goldberg, Matthew S., Mehellou, Youcef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258795/
https://www.ncbi.nlm.nih.gov/pubmed/37248632
http://dx.doi.org/10.1021/acs.jmedchem.3c00555
Descripción
Sumario:[Image: see text] Ubiquitin phosphorylation by the mitochondrial protein kinase PTEN-induced kinase 1 (PINK1), upon mitochondrial depolarization, is an important intermediate step in the recycling of damaged mitochondria via mitophagy. As mutations in PINK1 can cause early-onset Parkinson’s disease (PD), there has been a growing interest in small-molecule activators of PINK1-mediated mitophagy as potential PD treatments. Herein, we show that N(6)-substituted adenosines, such as N(6)-(2-furanylmethyl)adenosine (known as kinetin riboside) and N(6)-benzyladenosine, activate PINK1 in HeLa cells and induce PINK1-dependent mitophagy in primary mouse fibroblasts. Interestingly, pre-treatment of HeLa cells and astrocytes with these compounds inhibited elevated ubiquitin phosphorylation that is induced by established mitochondrial depolarizing agents, carbonyl cyanide m-chlorophenyl-hydrazine and niclosamide. Together, this highlights N(6)-substituted adenosines as progenitor PINK1 activators that could potentially be developed, in the future, as treatments for aged and sporadic PD patients who have elevated phosphorylated ubiquitin levels in the brain.